Active Biotech AB (publ) (ACTI.ST) Research

Active Biotech AB (publ) is a Swedish biotechnology firm focused on developing pharmaceutical treatments for oncology and immunological conditions. Its product pipeline features Tasquinimod, a small molecule immunomodulator currently in Phase Ib/IIa clinical trials for treating multiple myeloma. Another key asset is Laquinimod, an immunomodulator undergoing Phase I development for various inflammatory eye disorders, including uveitis. Additionally, the company is advancing Naptumomab, an anti-cancer immunotherapy, which is in Phase Ib/II clinical trials for individuals with advanced solid tumors. Naptumomab's development and commercialization are managed through a licensing partnership with NeoTX Therapeutics Ltd. Founded in 1983, Active Biotech AB (publ) is headquartered in Lund, Sweden.

Market snapshot

Symbol
ACTI.ST
Price
$6.10
Day change
+3.66%
Market cap
$16.1B
P/E ratio
-265.00x
52-week range
3.7-20.11431
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Alligator Bioscience AB (publ) (ATORX.ST)
  • Biosergen AB (BIOSGN.ST)
  • Biovica International AB (publ) (BIOVIC-B.ST)
  • Iconovo AB (publ) (ICO.ST)
  • Immunovia AB (publ) (IMMNOV.ST)
  • Nanologica AB (publ) (NICA.ST)
  • NextCell Pharma AB (NXTCL.ST)
  • Pila Pharma AB (publ) (PILA.ST)

Open Active Biotech AB (publ) (ACTI.ST) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.